Table 1 C-index analysis of the prognostic accuracy of gankyrin, STAT3 and other variables for OS and PFS in the training, validation, and combined cohorts.

From: Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma

 

Overall survival

Progression-free survival

Index (95% CI)

Training cohort (n = 128)

Validation cohort (n = 128)

Combine cohort (n = 256)

Training cohort (n = 128)

Validation cohort (n = 128)

Combined cohort (n = 256)

TNM stage

0.7225 (0.6433–0.7617)

0.7138 (0.6344–0.7633)

0.7334 (0.6654–0.7815)

0.6823 (0.6113–0.7209)

0.6674 (0.6011–0.7069)

0.6787 (0.6141–0.7133)

SSIGN

0.7159 (0.6367–0.7551)

0.7013 (0.6218–0.7408)

0.7205 (0.6513–0.7697)

0.6837 (0.6149–0.7252)

0.6637 (0.6043–0.7188)

0.6704 (0.6089–0.7206)

Gankyrin

0.7519 (0.6330–0.8608)

0.7617 (0.6437–0.8834)

0.7942 (0.6880–0.9061)

0.7387 (0.6302–0.8359)

0.7138 (0.6179–0.8271)

0.7277 (0.6241–0.8305)

STAT3

0.7234 (0.6266–0.7689)

0.7211 (0.6170–0.7752)

0.7301 (0.6327–0.7875)

0.7089 (0.6201–0.7577)

0.6912 (0.6137–0.7687)

0.7051 (0.6185–0.7618)

Gankyrin + STAT3

0.8054 (0.6611–0.8716)

0.8055 (0.6747–0.8663)

0.8183 (0.7188–0.9278)

0.7622 (0.6780–0.8364)

0.7535 (0.6614–0.8263)

0.7589 (06684–0.8326)

TNM stage + SSIGN

0.7825 (0.6521–0.8929)

0.7779 (0.6461–0.8898)

0.8086 (0.6945–0.9226)

0.7461 (0.6454–0.8407)

0.7210 (0.6336–0.8313)

0.7342 (0.6431–0.8354)

Gankyrin + STAT3 + TNM stage

0.8520 (0.7328–0.9412)

0.8461 (0.7237–0.9484)

0.8569 (0.7477–0.9561)

0.8130 (0.6810–0.8949)

0.8068 (0.6842–0.8894)

0.8077 (0.6813–0.8941)

Gankyrin + STAT3 + SSIGN

0.8471 (0.7299–0.9343)

0.8393 (0.7174–0.9311)

0.8535 (0.7412–0.9457)

0.8134 (0.6826–0.8991)

0.7971 (0.6704–0.8837)

0.8041 (0.6803–0.8857)

Back to article page